Credit Suisse Group Reiterates “Buy” Rating for Elanco Animal Health (NYSE:ELAN)

Elanco Animal Health (NYSE:ELAN)‘s stock had its “buy” rating reaffirmed by Credit Suisse Group in a report issued on Wednesday, AnalystRatings.com reports.

ELAN has been the subject of several other reports. ValuEngine raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, March 4th. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Tuesday, December 24th. Gabelli reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, January 14th. Zacks Investment Research upgraded shares of Elanco Animal Health from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Finally, Bank of America upgraded shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $34.00 target price for the company in a research note on Thursday, December 19th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Elanco Animal Health presently has a consensus rating of “Buy” and a consensus target price of $33.83.

Elanco Animal Health stock traded up $1.01 during midday trading on Wednesday, hitting $19.62. 4,486,100 shares of the company were exchanged, compared to its average volume of 6,817,675. The firm has a market capitalization of $7.50 billion, a PE ratio of 103.27, a price-to-earnings-growth ratio of 1.13 and a beta of 0.81. Elanco Animal Health has a fifty-two week low of $15.17 and a fifty-two week high of $35.46. The business has a fifty day simple moving average of $26.56 and a two-hundred day simple moving average of $27.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.62 and a current ratio of 2.90.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $0.23 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.23. Elanco Animal Health had a return on equity of 7.33% and a net margin of 2.21%. The company had revenue of $787.00 million during the quarter, compared to the consensus estimate of $790.83 million. During the same period in the previous year, the company posted $0.29 earnings per share. Elanco Animal Health’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, equities analysts expect that Elanco Animal Health will post 1.11 earnings per share for the current year.

In other Elanco Animal Health news, Director Michael J. Harrington purchased 4,000 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average cost of $23.84 per share, for a total transaction of $95,360.00. Following the completion of the transaction, the director now owns 16,799 shares of the company’s stock, valued at approximately $400,488.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John P. Bilbrey acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $25.15 per share, with a total value of $75,450.00. Following the purchase, the director now owns 8,016 shares in the company, valued at approximately $201,602.40. The disclosure for this purchase can be found here. Insiders have acquired 15,000 shares of company stock valued at $388,329 in the last three months. Insiders own 0.04% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Institutional & Family Asset Management LLC purchased a new stake in shares of Elanco Animal Health in the third quarter valued at about $28,000. Chevy Chase Trust Holdings Inc. purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $33,000. RMR Wealth Builders purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $42,000. Citizens Financial Group Inc RI grew its stake in shares of Elanco Animal Health by 62.5% in the 4th quarter. Citizens Financial Group Inc RI now owns 1,519 shares of the company’s stock valued at $45,000 after buying an additional 584 shares during the period. Finally, Evolution Wealth Advisors LLC grew its stake in shares of Elanco Animal Health by 2,726.8% in the 4th quarter. Evolution Wealth Advisors LLC now owns 1,583 shares of the company’s stock valued at $47,000 after buying an additional 1,527 shares during the period. 92.68% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.